TrialEuropean urology oncology2022

Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.

Johannes Alfred Witjes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.